CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
EurekAlert!7h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
technologynetworks19h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...
Armed robbery in Revesby7h
CRISPR-Cas9 Phase 2 Boosts Hereditary Angioedema Hope
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
FierceBiotech1h
Poseida's HAE gene therapy edits primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
A Closer Look at Intellia Therapeutics's Options Market Dynamics
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Intellia Therapeutics over the recent three months.
healthday3h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
Organoids Market Size To Reach $15.01 Billion By 2031 | CAGR 22.3%: The Insight Partners
Overview of Report Findings Market Growth : The organoid market is expected to reach U.S. $ 15.01 billionby 2031 from U.S. $ ...
Singularity Hub23h
Scientists Just Discovered Over 70,000 Bizarre New Viruses With AI
Charting the "dark matter" of the viral universe has implications not just for biotechnology—but potentially for battling the ...
Science Daily1d
Gene editing approach paves the way to first-in-human clinical trial for rare genetic disease
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...